Article
Medicine, General & Internal
Ahmad Albshesh, Lian Bannon, Tali Sharar Fischler, Marie Truyens, Stephan R. R. Vavricka, Katja Tepes, Daniela Pugliese, Edoardo V. V. Savarino, Eran Zittan, David Drobne, Xavier Roblin, Ariella Bar-Gil Shitrit, Alessandro Armuzzi, Triana Lobaton, Nitsan Maharshak, Henit Yanai, Shomron Ben-Horin, Uri Kopylov
Summary: The effectiveness of anti-TNF or ustekinumab as a second-line biologic after vedolizumab failure in patients with Crohn's disease was investigated. The results showed that there was no significant difference in the clinical response, remission rate, and discontinuation rate between the use of anti-TNF and ustekinumab as a second-line therapy.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Gastroenterology & Hepatology
Rayer Cassandra, Maria Nachury, Bourreille Arnaud, Roblin Xavier, Peyrin-Biroulet Laurent, Viennot Stephanie, Flamant Mathurin, Laharie David, Caron Benedicte, Dewitte Marie, Siproudhis Laurent, Fumery Mathurin, Bouguen Guillaume
Summary: This study compared the efficacy of biologics in patients with Crohn's disease who failed the first anti-TNF agent. The results showed that VDZ, UST, and a second anti-TNF agent exhibited similar efficacy in the short term, but UST had shorter drug maintenance.
BMC GASTROENTEROLOGY
(2022)
Article
Gastroenterology & Hepatology
Carl Eriksson, Jonas Soderling, Sara Karlqvist, Gabriella Broms, Asa H. Everhov, Daniel F. Bergemalm, Jonas Ludvigsson, Ola Olen, Jonas Halfvarson
Summary: This study aimed to compare and evaluate the comparative effectiveness and safety of ustekinumab and anti-TNF treatment in patients with Crohn's disease who failed first-line anti-TNF therapy. The results showed no significant differences in effectiveness or safety between ustekinumab and anti-TNF treatment in patients with prior exposure to anti-TNF therapy for Crohn's disease.
DIGESTIVE DISEASES AND SCIENCES
(2023)
Article
Gastroenterology & Hepatology
Marco Vincenzo Lenti, Vivien Dolby, Tanya Clark, Veronica Hall, Suzanne Tattersall, Francesca Fairhurst, Catherine Kenneth, Rachael Walker, Karen Kemp, Simon Borg-Bartolo, Jimmy K. Limdi, Jo Taylor, Tristan Townsend, Sree Subramanian, Daniel Storey, Arash Assadsangabi, Catherine Stansfield, Paul Smith, Debra Byrne, Annalisa De Silvestri, Christian P. Selinger
Summary: The study showed that ustekinumab was more effective than vedolizumab at 14 weeks in CD patients, but there was no significant difference between the two at 52 weeks. Ustekinumab was found to be effective and well tolerated in this real-world cohort.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Gastroenterology & Hepatology
Gadi Howard, Dror Weiner, Itzhak Bar-Or, Arie Levine
Summary: The study demonstrates the efficacy of dual biologic therapy with vedolizumab and ustekinumab in treating highly refractory patients who have failed previous monotherapy.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Fabio Salvatore Macaluso, Mauro Grova, Marica Saladino, Maria Cappello, Maria Giulia Demarzo, Antonino Carlo Privitera, Emiliano Giangreco, Serena Garufi, Sara Renna, Angelo Casa, Marco Ventimiglia, Walter Fries, Ambrogio Orlando
Summary: This study assessed the effectiveness of Ustekinumab (UST) and Vedolizumab (VDZ) as third-line biologic therapy in patients with Crohn's disease (CD) and found that both treatments were highly effective.
DIGESTIVE AND LIVER DISEASE
(2023)
Article
Gastroenterology & Hepatology
Pauline Riviere, Caitlyn Kanters, Gauthier Pellet, Alexander Ni, Marianne Hupe, Nesrine Aboulhamid, Florian Poullenot, Alain Bitton, Frank Zerbib, Peter L. Lakatos, Waqqas Afif, David Laharie, Talat Bessissow
Summary: This study aimed to compare the efficacy of anti-tumor necrosis factor agents and ustekinumab in patients with Crohn's disease. The results showed that anti-tumor necrosis factor agents as first-line biological therapy were associated with higher response rates at 3 months compared to ustekinumab.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Medicine, General & Internal
Ahmad Albshesh, Joshua Taylor, Edoardo Savarino, Marie Truyens, Alessandro Armuzzi, Davide G. Ribaldone, Ariella Bar-Gil Shitrit, Morine Fibelman, Pauliina Molander, Claire Liefferinckx, Stephane Nancey, Mohamed Korani, Mariann Rutka, Manuel Barreiro-de Acosta, Viktor Domislovic, Gerard Suris, Carl Eriksson, Catarina Alves, Afroditi Mpitouli, Caroline di Jiang, Katja Tepes, Marina Coletta, Kalliopi Foteinogiannopoulou, Javier P. Gisbert, Hadar Amir-Barak, Mohamed Attauabi, Jakob Seidelin, Waqqas Afif, Carla Marinelli, Triana Lobaton, Daniela Pugliese, Nitsan Maharshak, Anneline Cremer, Jimmy K. Limdi, Tamas Molnar, Borja Otero-Alvarin, Zeljko Krznaric, Fernando Magro, Konstantinos Karmiris, Tim Raine, David Drobne, Ioannis Koutroubakis, Maria Chaparro, Henit Yanai, Johan Burisch, Uri Kopylov
Summary: This retrospective multicenter cohort study investigated the effectiveness of vedolizumab (VDZ) and ustekinumab (UST) as third-class biologic therapies in patients with Crohn's disease. The study found that both VDZ and UST were effective in more than half of the patients with CD, with no significant differences in effectiveness between the two agents.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Gastroenterology & Hepatology
Hadrien Alric, Aurelien Amiot, Julien Kirchgesner, Xavier Treton, Mathieu Allez, Yoram Bouhnik, Laurent Beaugerie, Franck Carbonnel, Antoine Meyer
Summary: The VDZ-CDST can predict clinical remission and SFCR at week 48 for vedolizumab, but not for ustekinumab, in CD patients refractory or intolerant to anti-TNF therapy.
INFLAMMATORY BOWEL DISEASES
(2022)
Article
Gastroenterology & Hepatology
Pauline Wils, Philippe Seksik, Carmen Stefanescu, Stephane Nancey, Matthieu Allez, Guillaume Pineton de Chambrun, Romain Altwegg, Cyrielle Gilletta, Lucine Vuitton, Stephanie Viennot, Melanie Serrero, Mathurin Fumery, Guillaume Savoye, Michael Collins, Felix Goutorbe, Hedia Brixi, Guillaume Bouguen, Noemie Tavernier, Medina Boualit, Aurelien Amiot, Vered Abitbol, David Laharie, Benjamin Pariente
Summary: This retrospective cohort study evaluated maternal and neonatal complications and management of vedolizumab or ustekinumab in pregnant women with IBD. The results showed that these drugs did not have negative effects on maternal or neonatal outcomes during pregnancy. Further prospective studies are needed to confirm these findings.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2021)
Article
Gastroenterology & Hepatology
Michael D. Kappelman, Sruthi Adimadhyam, Laura Hou, Audrey E. Wolfe, Samantha Smith, Andrew L. Simon, Erick Moyneur, Juliane S. Reynolds, Sengwee Toh, Angela Dobes, Lauren E. Parlett, Kevin Haynes, Mano Selvan, Qianli Ma, Vinit Nair, Jessica Burris, Jennifer E. Dorand, Ghadeer K. Dawwas, James D. Lewis, Millie D. Long
Summary: This study compared the effectiveness and safety of ustekinumab and vedolizumab in a large US population of Crohn's disease patients who had lost response or become intolerant to anti-TNF therapy. The findings showed no difference in treatment persistence between the two drugs, but ustekinumab was associated with lower rates of all-cause hospitalization, nonsurgical CD hospitalization, and hospitalization for infection.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Michelle Vu, Sabyasachi Ghosh, Kandavadivu Umashankar, Laura Weber, Christina Landis, Ninfa Candela, Benjamin Chastek
Summary: This study retrospectively examined the surgery rates of biologic-naive patients with Crohn's disease treated with vedolizumab or ustekinumab. The findings suggest that vedolizumab is more effective than ustekinumab in reducing the risk and incidence of CD-related surgery.
BMC GASTROENTEROLOGY
(2023)
Article
Pharmacology & Pharmacy
A. Tursi, G. Mocci, A. Cuomo, L. Allegretta, G. Aragona, R. Colucci, N. Della Valle, A. Ferronato, G. Forti, F. Gaiani, M. G. Graziani, R. Lorenzetti, F. Luzza, P. Paese, A. Penna, R. Pica, S. Piergallini, G. Pranzo, S. Rodino, A. Scarcelli, C. Zampaletta, C. Cicerone, A. Cocco, G. De'Angelis, L. Donnarumma, M. Franceschi, S. Gallina, G. Grasso, T. Larussa, I Luppino, R. Faggiani, L. Fanigliulo, C. Pagnini, P. Perazzo, R. Sacco, L. Sebkova, S. Scorza, M. Serio, A. De Monti, M. Picchio, W. Elisei, G. Maconi
Summary: UST appears to be highly effective and safe in CD patients who have not responded to other biologic treatments, particularly when used as a second-line therapy.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
(2021)
Article
Gastroenterology & Hepatology
Valdes Delgado Teresa, Olmedo Martin Raul, Iborra Marisa, Herrera de Guise Claudia, Fuentes-Valenzuela Esteban, Melcarne Luigi, Martin-Rodriguez Ma Mar, Kolle Casso Lilyan, De Castro Parga Luisa, Ponferrada Diaz Angel, Vicente Lidon Raquel, Mancenido Marcos Noemi, Velayos Jimenez Benito, Lazaro Saez Marta, Lopez Cauce Beatriz, Mesonero Gismero Francisco, Gilabert Alvarez Pau, Arguelles-Arias Federico
Summary: This study evaluated the effectiveness and safety of ustekinumab in bio-naive patients with Crohn's disease. The results showed that ustekinumab had high rates of clinical and biological remission and a favorable safety profile. It suggests that ustekinumab could be considered as a first-line therapy for Crohn's disease patients.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
(2023)
Article
Pharmacology & Pharmacy
Fatema Alrashed, Israa Abdullah, Ahmad Alfadhli, Mohammad Shehab
Summary: This study evaluated the effectiveness of ustekinumab and vedolizumab in patients with inflammatory bowel disease who had previously failed anti-TNF therapy. The results showed that both drugs were effective in achieving clinical outcomes, with ustekinumab demonstrating slightly higher percentages of reaching target outcomes compared to vedolizumab.
FRONTIERS IN PHARMACOLOGY
(2023)
